A survey among breast cancer specialists on the low uptake of therapeutic prevention with tamoxifen or raloxifene

Article English CLOSED
Noonan, S; Pasa, A; Fontana, V; Caviglia, S; Bonanni, B; Costa, A; Smith, SG; Peccatori, F; DeCensi, A;
  • Publisher: American Association for Cancer Research

With this survey, we aimed to address the reasons why physicians are reluctant to prescribe breast cancer preventive therapy with the selective oestrogens receptor modulators (SERMs) tamoxifen or raloxifene despite a strong evidence of efficacy. A self-administered 5-po... View more
Share - Bookmark